New study tests better smoking cessation plans for cancer patients

NCT ID NCT06218823

Completed Disease control Sponsor: University of Wisconsin, Madison Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested two different smoking cessation treatments in 52 adult cancer patients who had been diagnosed within the past 3 years. One group received a 12-week course of the medication varenicline plus 7 counseling calls tailored to cancer patients. The other group received a standard approach: 2 weeks of nicotine patches plus 3 brief counseling calls. The main goal was to see which treatment helped more patients stay smoke-free 26 weeks after their quit date.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: varenicline and nicotine patch
What this could lead to: If successful, this could identify a more effective way to help cancer patients quit smoking, improving their overall health and treatment outcomes.
What could go wrong: This is a small pilot study with only 52 participants, so results may not apply to all cancer patients. The treatments may not show a clear difference in effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm Smoking Cessation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER SMOKING CESSATION

Contacts and locations

Locations

UW Carbone Cancer Center

Madison, Wisconsin, 53792, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.